By blocking the activity of Src and Akt through pharmacological inhibitors such as dasatinib [97] and fucoxanthin [100], respectively, aberrant splicing events that facilitate chemoresistance in cervical cancer can be reversed and promote a complete therapy response in advanced metastatic disease. The gene discussed is AKT1; the disease is cervical carcinoma.